Education
About Us
Working with TipRanks
Follow Us
Cryosite Limited (AU:CTE)
ASX:CTE
CTE Stock Chart & Stats
AU$1.00
-AU$0.05(-6.02%)
At close: 4:00 PM EST
AU$1.00
-AU$0.05(-6.02%)
Day’s Range― - ―
52-Week RangeAU$0.60 - AU$1.30
Previous CloseN/A
Volume1.46K
Average Volume (3M)1.97K
Market Cap
AU$58.82M
Enterprise ValueAU$55.78M
Total Cash (Recent Filing)AU$5.06M
Total Debt (Recent Filing)AU$2.27M
Price to Earnings (P/E)31.1
Beta-0.67
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding48,809,563
10 Day Avg. Volume3,337
30 Day Avg. Volume1,969
Financial Highlights & Ratios
PEG Ratio8.08
Price to Book (P/B)15.22
Price to Sales (P/S)2.58
P/FCF Ratio24.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Profitability MarginsCryosite's high gross (62.98%) and net (13.35%) margins reflect structural pricing power and operational efficiency in temperature‑controlled biorepository services. Sustained margins support reinvestment into facilities and technology, provide a cushion versus volume swings, and improve long‑term resilience of cash generation.
Consistent Revenue GrowthA 9.85% YoY revenue increase evidences durable demand for recurring biostorage and sample management services. Given the subscriptionlike revenue from long‑term storage and ongoing handling fees, steady top‑line growth supports predictable revenue streams and scalable margins over a multi‑quarter horizon.
High Return On EquityROE of 78.86% indicates very efficient use of shareholder capital to generate profits in an asset‑light service business. High capital productivity can translate into strong shareholder returns if management maintains disciplined reinvestment and controls leverage, enhancing long‑term value creation.
Bears Say
Declining Free Cash Flow GrowthA 32.88% decline in free cash flow growth signals weakening cash generation momentum. Reduced FCF constrains the company's ability to internally fund capex, expand facilities, or pay down debt, increasing dependence on external financing and limiting strategic flexibility over the medium term.
Earnings Not Fully Cash‑BackedOCF falling short of net income indicates that reported earnings are not fully converting to cash, potentially due to accruals or working capital pressures. Persistent conversion gaps raise concerns about earnings quality and may necessitate additional liquidity or financing during growth or stress periods.
Material Leverage RelianceA D/E near 0.95 and a low equity ratio point to meaningful reliance on debt financing. This reduces financial flexibility, increases interest and refinancing exposure, and can amplify downside risk if cash flows weaken or interest rates rise, constraining longer‑term strategic options.
Cryosite Limited News
CTE FAQ
What was Cryosite Limited’s price range in the past 12 months?
Cryosite Limited lowest share price was AU$0.60 and its highest was AU$1.30 in the past 12 months.
What is Cryosite Limited’s market cap?
Cryosite Limited’s market cap is AU$58.82M.
When is Cryosite Limited’s upcoming earnings report date?
Cryosite Limited’s upcoming earnings report date is Aug 21, 2026 which is in 181 days.
How were Cryosite Limited’s earnings last quarter?
Currently, no data Available
Is Cryosite Limited overvalued?
According to Wall Street analysts Cryosite Limited’s price is currently Overvalued.
Does Cryosite Limited pay dividends?
Cryosite Limited pays a Annually dividend of AU$0.02 which represents an annual dividend yield of N/A. See more information on Cryosite Limited dividends here
What is Cryosite Limited’s EPS estimate?
Cryosite Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cryosite Limited have?
Cryosite Limited has 48,809,563 shares outstanding.
What happened to Cryosite Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Cryosite Limited?
Currently, no hedge funds are holding shares in AU:CTE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cryosite Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
15.34%
12-Months-Change
Fundamentals
Return on Equity
98.18%
Trailing 12-Months
Asset Growth
-1.26%
Trailing 12-Months
Company Description
Cryosite Limited
Cryosite Limited offers outsourced clinical trials logistic services in Australia. It operates through two segments, Clinical Trials and Biological Services Logistics, and Cord Blood and Tissues Storage. The Clinical Trials and Biological Services Logistics segment provides specialist temperature-controlled storage, labelling, status management, secondary packaging, schedule drug distribution, destruction, returns management, comparator sourcing, import, export, validated transport, and biological storage solutions to the clinical trials, and research and pharmaceutical industry. The Cord Blood and Tissues Storage segment offers long term storage solutions for cord blood and tissue samples. It serves research, medical, pharmaceutical, veterinary, and biotechnology industries. The company was incorporated in 1999 and is based in South Granville, Australia.
Technical Analysis
BCAL Diagnostics Limited
―
Rhythm Biosciences Ltd.
―
Lumos Diagnostics Holdings Ltd.
―
Inoviq Ltd
―
Microba Life Sciences Limited
―
Options Prices
Currently, No data available
---